

# A Conversation with Nancy Flournoy

William F. Rosenberger

*Abstract.* Nancy Flournoy was born in Long Beach, California, on May 4, 1947. After graduating from Polytechnic School in Pasadena in 1965, she earned a B.S. (1969) and M.S. (1971) in biostatistics from UCLA. Between her bachelors and masters degrees, she worked as a Statistician I for Regional Medical Programs at UCLA. After receiving her master's degree, she spent three years at the Southwest Laboratory for Education Research and Development in Seal Beach, California. Flournoy joined the Seattle team pioneering bone marrow transplantation in 1973. She moved with the transplant team into the newly formed Fred Hutchinson Cancer Research Center in 1975 as Director of Clinical Statistics, where she supervised a group responsible for the design and analysis of about 80 simultaneous clinical trials. To support the Clinical Division, she supervised the development of an interdisciplinary shared data software system. She recruited Leonard B. Hearne to create this database management system in 1975 (and married him in 1978). While at the Cancer Center, she was also at the University of Washington, where she received her doctorate in biomathematics in 1982. She became the first female director of the program in statistics at the National Science Foundation (NSF) in 1986. She received service awards from the NSF in 1988 and the National Institute of Statistical Science in 2006 for facilitating interdisciplinary research. Flournoy joined the Department of Mathematics and Statistics at American University in 1988. She moved as department chair to the University of Missouri in 2002, where she became Curators' Distinguished Professor in 2012.

While at the Cancer Center, Flournoy documented the graft-versus-leukemia effect in humans and discovered a source of frequent lethal viral infections in the bone marrow transplant patients. Later she was influential in developing adaptive experimental designs. Her numerous honors include fellow of the Institute of Mathematical Statistics (1990), the American Statistical Association (1992), the World Academy of Arts and Sciences (1992) and the American Academy for the Advancement of Science (1993). She has received the COPSS Scott (2000) and David (2007) awards, and the Norwood (2012) award from the University of Alabama.

*Key words and phrases:* Adaptive designs, clinical trials, data coordinating center, random walk rules, up-and-down procedures.

## 1. EARLY LIFE

**Rosenberger:** Tell us a little about your early life. Where did you grow up and what did your parents do?

---

*William F. Rosenberger is University Professor and Chairman, Department of Statistics, George Mason University, 4400 University Drive MS 4A7, Fairfax, Virginia 22030-4444, USA (e-mail: wrosenbe@gmu.edu).*

**Flournoy:** I was born in Long Beach, CA, and grew up in Los Angeles County in a lemon orchard surrounded by oil wells and a flood plain. There was a dairy farm nearby and we had a donkey. My father was a plumbing contractor who plumbed Los Angeles: restaurants, dormitories, cemeteries. He had 11 trucks go out every day. My Mom was always unhappy about not finishing college, so she enrolled in college when I



FIG. 1. Nancy at home in a part of Los Angeles County that was then called Potero Heights, 1949.

went to college and then directed a preschool for many years. I have three brothers and one sister. I was sent to Polytechnic School in Pasadena as a sophomore in high school. On the entrance exam I had the second highest score in math in history, but I flunked the English exam because I didn't know the words in the instructions. (So even then I had a one-sided brain!)

**Rosenberger:** As a young person, were you interested in mathematics, statistics, data? What made you excited about statistics?

**Flournoy:** High school algebra really made me happy; I would lay on the floor and work problems for hours. I had a new female instructor whose husband had gotten a professorship across the street at Cal Tech while she just landed a high school job; her anger came through and I got the message that mathematics is worth being passionate about.

My love of statistics came as a junior at UCLA, when I took a course taught by Don Ylvisaker. I just assumed that Don was a great teacher for all time, but he later told me that he never had another class like it. Four or five students from that class went on to get doctorates in statistics.

**Rosenberger:** You were fortunate to be at UCLA at a time when there were some of the great names in biostatistics: Abdelmonen Afifi, Frank Massey, Wil Dixon, Olive Dunn, Virginia Clark. What professors excited you at UCLA?



FIG. 2. Nancy at her graduation from Polytechnic School, Pasadena, 1965.

**Flournoy:** Afifi was the young dynamic professor and taught out of Scheffé; all the students loved Afifi. Dixon had a bimodal distribution among the students; you either loved him or hated him. He put out a thousand ideas a minute; if you paid close attention, you would find they were pearls. It was a challenge to get what he was saying as he didn't change the tone of his voice when he switched from one topic to another. He taught the power of data analysis as a tool for learning and a thousand little ways to make the data sing. I had a class with Frank Massey; I learned a lot, but he was quiet and not dynamic.

**Rosenberger:** Did you have any connection to the Department of Statistics? You mentioned Ylvisaker. What about Paul Hoel?

**Flournoy:** A separate statistics department did not exist at that time; it was a math department with a few statisticians. I used the Hoel, Port and Stone probability book when it was just a set of notes. I don't think Hoel was the instructor though.

**Rosenberger:** What interested you in biostatistics?

**Flournoy:** Most of the statistics courses that were offered at UCLA were in the Department of Biostatistics. Prior to taking statistics, I had loved biochemistry

and was a nutrition major, leading to my major in the School of Public Health (SPA). When I recognized that with a degree in nutrition, I would probably only be able to run a cafeteria in a hospital, I decided to get my degree in mathematics instead. I applied repeatedly to change from SPA to the College of Arts and Sciences (CAS), but my application would get turned down. In tears, I didn't know what to do. Then the SPA Dean asked why I was flunking out, which didn't make sense since I always had gotten As and Bs. They had lost all my records because I had changed names when I was previously married, and nothing followed me. So that's why they didn't accept me at CAS. By the time this got settled, I had enough credits to get a degree in biostatistics.

## 2. GRADUATE SCHOOL

**Rosenberger:** What did you do after you graduated? How did you get to graduate school?

**Flournoy:** When I got a job at Regional Medical Programs as a Statistician I, one old man would come around and ask me to add numbers; I told him he could hire a statistical clerk for half my salary. I was told that, as a young woman, my presentations were not credible. So they hired a male DrPh to present my reports in his name. As a mild way of protesting, I put my hair in a bun, dyed it white, and got fired. They said I was an "uppity woman." At that time, Virginia Clark

was department chair. She said, "We have a fellowship, why don't you come to grad school?" I have some happy memories of my master's program at UCLA: Olive Dunn supervised my master's thesis; Mary Ann Hill was a great teaching assistant for Dixon's class; Carol Newton taught a mean FORTRAN programming course; and Ray and Jean Mickey were influential in my career decisions.

**Rosenberger:** When you won the David Award, you talked about meeting F. N. David. Tell us about that.

**Flournoy:** I was in the Los Angeles chapter of the ASA; around 1972, a group of us carpoled out to UC Riverside where David was giving a talk. She had a strong presence, standing with one leg up on a staircase and smoking a cigar while she talked. It was a roomful of people, and she exuded such confidence. So I immediately started smoking cigars. I had been used to seeing female statisticians such as Clark and Dunn behind a desk and not commanding an audience.

**Rosenberger:** How did you get to University of Washington (UW)?

**Flournoy:** After the M.S., I thought I knew everything about statistics. I got a job at Southwest Education and Laboratory for Research, where there were a lot of education psychologists who were into experimental design. On my second day, they presented me with computer output that had more than one error term; I had the good sense to keep my mouth shut. I immediately called Wil Dixon and asked what they were



FIG. 3. Nancy with her parents, Elizabeth Blincoe and Carr Irvine Flournoy, at her graduation from the University of Washington in 1982.

talking about. He replied, “Oh well, we can’t teach you everything.” He suggested I get a book by Walt Federer. The book was out of print, but Walt got a preprint from India and sent it to me; so I spent my nights reading Federer’s book.

Later, I was trying to read the *Journal of the American Statistical Association* to implement some of the stuff I wanted to do, and I found I couldn’t read the literature. I also wanted to escape the smog of Los Angeles. So I applied to the UW, my only application. Dick Kronmal said there was a research assistant position with the bone marrow transplant team, which was then located in the Old Public Hospital (recently Amazon) in Seattle.

At that time, there was no statistics department at UW. The mathematical statistics courses were taught in the Department of Mathematics. I took the mathematical statistics sequence from Galen Shorack. I had courses from Ron Pyke and Fritz Schultz in nonparametrics. Shortly after Fritz left for Boeing, the remaining statistics faculty formed the Department of Statistics. In the Department of Biostatistics, there were some female faculty: Paula Diehr and Pat Wahl. I took the first categorical data analysis class taught at UW from Norman Breslow. He gave quizzes at the end of class, so I never paid so much attention in a course before. I took survival from Ross Prentice early in the days of the Cox proportional hazards model.

**Rosenberger:** What was it like working with your dissertation advisor, Lloyd Fisher?

**Flournoy:** It worked out well because we have similar work styles. Both of us had busy consulting lives; we would schedule meetings and get our business done.

### 3. THE SEATTLE BONE MARROW TRANSPLANTATION TEAM

**Rosenberger:** Today every street corner seems to have a contract research organization for data coordinating centers on large clinical trials. But when you went to the Fred Hutchinson Cancer Research Center, information technology was primitive, such places did not exist. You had to create that environment on your own. What was it like? What were the challenges?

**Flournoy:** That’s an interesting story. Dick Kronmal had invested a lot of effort in creating a database management system without requiring a rectangular data structure. Updates required physically sorting the cards (remember all data records had to fit into the 80 digits of a Hollerith punch card—so I tend to use

the words “card” and “record” interchangeably). There was a transplant data set in place with seven different kinds of cards. Kronmal had E. Donnal “Don” Thomas (Director of the Clinical Research Division at the Cancer Center) buy a computer. The computer weighed 50 pounds (I could toss it in my van and take it home; the cost was about \$50,000), and data storage was on Phillips cassette tapes. Records could be transmitted across the phone wires and then integrated into the database at UW. Initially, there was not much data (only 10 patients) and the first update took my whole computing budget for the year! What I did then for some period of time was, when it was time to do an update, punch cards of the whole database and the new dataset; I would physically sort and merge the cards by hand and load them into SPSS. That was my “dirty laundry” story because the laundromat had big long tables and I sorted cards while doing laundry. Kronmal told me that, if I had any trouble with my new computer, I should call Leonard Hearne. Index sequential files were brand new at that time, and Leonard used them to create an early database management system before the word was in the literature (see Flournoy and Hearne, 1981, 1990a, 1990b). We used it for several years until a commercial system came on the market. At site visits, someone would ask a question and I would pass a note down to a programmer, who would extract the answer in 15 minutes or so. We set the bar for oncology programs.

Ross Prentice came from the University of Waterloo with a box of cards on the Cox proportional hazards model; we were really early using that. The doctors were smart enough to understand the limitations in using discriminant analysis and they were thrilled to be able to incorporate censored survival data in their regression models. My work documenting graft vs. leukemia in humans was very important (see Weiden et al., 1979, 1981a, 1981b, 1981c). One hypothesis motivating the development of bone marrow transplantation was that the marrow graft would attack residual leukemia also. Immunological activity of the graft was apparent when the graft instigated an immunological attack on the patient. I modeled the impact of this attack on the relapse rate. The protection of the graft attack against relapse greatly complicated post-transplant treatment strategies. But our findings have withstood the test of time. It was, perhaps, the first major application of the proportional hazards model with time-dependent covariates.

**Rosenberger:** When you think of the success of the bone marrow transplant program (Don Thomas won

the Nobel prize in 1990 for developing bone marrow transplantation as a treatment for leukemia), how much did statistics and data management play a role in that? Do you think statistics and data management will ever get its due?

**Flournoy:** We had this rudimentary set of records that could be added onto infinitely. It started out that bacteriology wanted to add a card, then virology, then specific studies would add a card with their data. Before you knew it, we had an interdisciplinary shared database with assigned patient numbers so all the integrated data was available. I was able to say “do you know what they’re doing in virology that’s related” because I knew everybody’s data. It wasn’t until many years later that people started talking about having integrated shared databases. Most were established for billing purposes, not for research purposes. They are different constructs. Hospitals would archive data after the bill was paid but we wanted to keep it around forever.

When the program started, there was one of everybody (one statistician, one virologist, etc.), and we would sit around the table and share results. It was important to be influential and to catch problems in data collection and quality control before they got big. When working with new doctors, there were humps you had to get over because they would claim that there were no quality control issues: their lab people never made a mistake. A lot of negotiation had to go on before we could agree. Yes, we had a huge influence. Even randomization and blinding was controversial. If it was in the middle of the night the cards might get

shuffled; there was too much room for bias. We introduced them to a very careful randomization regimen for treatment assignments, with a 24 hour on-call person.

It will be hard for statistics and data management to ever get its full due because the doctors are so enamored of themselves (laughs). It’s really a strange system where the people with the least science background usually run the science. Also, the data management budget was always the first to be cut; yet it is very expensive to do a quality job.

**Rosenberger:** What has your role been in fostering interdisciplinary research?

**Flournoy:** Having conducted interdisciplinary research for more than a decade at the Cancer Center, I knew the power that teams of interdisciplinary researchers could bring to bear on important scientific questions. Coincidentally, when I went to the National Science Foundation (NSF) in 1986, the Division of Mathematical Sciences (DMS) had funded the Institute of Mathematical Statistics (IMS) to write a report on cross-disciplinary research. I watched the growth in their thinking as they interacted with each other. At the time, the discipline did not appreciate the role of applications in academic settings. I think I was able to influence the IMS cross disciplinary committee on the valuable nature of interdisciplinary work. The report of the committee had a dramatic effect on the discipline. The report proposed establishing the National Institute of Statistical Science. Since I was at NSF, I was able to promote the idea of establishing a broad institute that would work on problems of national importance.



FIG. 4. *Yash Mittal, first female director of the probability program, and Nancy, first female director of the statistics program, at NSF.*

At the same time, I would receive proposals from statisticians motivated by applications. Because our budget was small, I took such proposals around to the relevant disciplines that were involved, and was able to get some joint funding. This resulted in my getting an award in 1988 for facilitating the funding of these interdisciplinary projects. This also led to specific DMS requests for proposals for interdisciplinary research projects, which are now common throughout NSF.

#### 4. ADAPTIVE DESIGNS

**Rosenberger:** How did you get interested in adaptive designs?

**Flournoy:** While at the Cancer Center, the major program project grant had five-year reviews. When we prepared for the third one of these, we spent a year reviewing what we had done and how we would go forward. In the course of that retrospective, I developed some feelings about the two arm clinical trial. The standard ideas about the two arm clinical trials came from the Peto paper in the mid 70s (Peto et al., 1976, 1977). But, in my experience, a treatment is a point in a high dimensional space: involving drugs, radiation, including how much, how often; and one learned little about this high dimensional space using the traditional two arm clinical trial. For instance, we spent five years comparing A to B; but then we go back to the high dimensional space and pick out point C, and have another five years of experimentation and compare A to C. Then we compare C to D, and after 15 years we have knowledge of four points in a high dimensional space. I believed it would be more efficient and informative to know which direction we should head in the high dimensional space. So that led me to think about adaptive designs. I recommended several to the group and the physicians liked the ideas, but thought they may be too radical to get funded.

Another thing that promoted my interest was looking at pilot studies to decide what to take forward to larger studies. Bob Tsutukawa was visiting the Cancer Center from the University of Missouri at the time. I thought his Bayesian ideas were appealing and I used expert opinion for prior elicitation (see Flournoy, 1993). The prior was way off, so we wound up with a lot of toxicities. You just can't trust the best expert opinion of the best experts, and so there needed to be some way to use interim data faster to adapt and put much less weight on the prior. My later work showed how random walk rules could be constructed to do this (see Durham and

Flournoy, 1994; Durham, Flournoy and Rosenberger, 1997; Flournoy and Oron, 2015).

**Rosenberger:** The first time I heard the name Nancy Flournoy was in the context of the 1989 session on adaptive designs at Joint Statistical Meetings (JSM) in Washington. It turned out to be one of the most controversial sessions in the history of JSM. Talk about that.

**Flournoy:** My experience at NSF was that you don't make progress without community. One person alone doesn't get much done. So I had the idea that a JSM session on adaptive design would bring together people who are interested in adaptive designs. I didn't know anyone personally. I invited based on my impressions of their interests. I invited Don Berry, Richard Simon and Janis Hardwick. I gave a straightforward technical talk on the topic. The remainder of the session focused primarily on criticism of the extracorporeal membrane oxygenation (ECMO) trials (e.g., Barlett et al., 1985; O'Rourke et al., 1989; Ware, 1989). (The ECMO trial was an implementation of the randomized play-the-winner rule of Wei and Durham, 1978, in which 11 babies were assigned to an experimental arm, and all survived, while one baby assigned to the conventional arm, died. The historical death rate on the conventional arm was 80 percent.) To my dismay, all the negative focus of the session was directed toward the adaptive design aspect of the clinical trial, rather than on the sample size and what kind of sample size would be needed for the trial to be convincing. The press that was generated by this session set adaptive designs back a long time.

**Rosenberger:** How much do you think the failed ECMO trial inhibited the development of adaptive designs?

**Flournoy:** What would have been a reasonable approach? The original trial was unconvincing due to having few patients, in spite of the fact that a probabilistically reasonable stopping rule was applied. The controversy over the subsequent two arm trial in clinical research set back adaptive designs wrongly. The adaptive trial was so successful that only one baby died; is that bad?

**Rosenberger:** In your 1992 AMS/IMS/SIAM conference on adaptive designs (Flournoy and Rosenberger, 1995), you brought together some of the groundbreakers of adaptive designs along with a number of younger faculty who are now at the forefront of the discipline. At the opening session, you started by talking about the need to streamline the process of clinical trials, the end to phases and the incorporation of dynamic interim decisions. You said that will



FIG. 5. 1994 IMS Workshop on Sequential Analysis at University of North Carolina, Chapel Hill. Included are Nancy Flournoy (seated second from left), Lynne Billard (immediately behind Nancy), Janis Hardwick (to the right of Lynne), Bill Rosenberger (third row from back, middle), and Steve Durham (directly in front of right window).

revolutionize the way we do clinical trials, and that this conference would be an ambitious beginning to that revolution. Now, over two decades later, there are 70-some sessions on adaptive designs at the Joint Statistical Meetings, “big-pharma” working groups, Food and Drug Administration white papers and guidelines, companies like ADDPLAN, and CYTEL devoted to adaptive design software and everyone wants to do adaptive designs. What took so long?

**Flournoy:** ECMO made a steep hole to climb. We also had to develop theory. It was one thing to say “this is a good idea,” and another to adequately support it. Some ideas were NOT good. This includes a class of procedures that derive from stochastic approximation, that Val Fedorov coined “best intention” designs. In these designs, a target dose is estimated (such as the dose having a particular percent toxicity or one that maximizes some utility function); then that estimate is the dose given to the next subject. Some, including Lai and Robbins (1982), understood early on

that using this procedure without safeguards may result in treatment sequences that converge to the wrong dose. But others, including myself (Li, Durham and Flournoy, 1995), were enamored of this idea and ignorant of earlier warnings. This approach remains popular today even as recent publications are exposing just how misleading it can be (e.g., Azriel, 2012, Oron and Hoff, 2013).

In the 1980s, John Whitehead spent a year visiting the Cancer Center from the University of Reading, and promoted the idea of using sequential stopping rules taking censoring into account. Its value was so obvious that I expected that by 1990 every clinical trial would be using these techniques. So I focused instead on adaptive allocation. At American University (AU), I worked on theoretical problems in these areas. When I pulled my head out and looked around I was shocked to see that stopping rules incorporating censoring were not being used, except a bit in cancer. So things that seem obvious to some can take a long time to enter the

medical arena. Take the “3 + 3” dose escalation design as an example. It has been soundly discredited (Reiner, Paoletti and O’Quigley, 1999; Lin and Shih, 2001), and yet remains a standard practice in oncology phase I trials.

Adaptive allocation is still in its infancy compared to sequential monitoring and stopping. Now there has developed a new belief that simulation is adequate for assessing an adaptive design. But relying solely on simulation muddies the water because there is no global view of what is driving the design. In addition, there are many papers in the literature that report only averages over simulations without measures of variability. When you consider measures of variability, a completely different picture emerges (Oron and Hoff, 2013). I fervently believe in developing the theory underlying classes of designs. Fortunately, many people are interested in working on the theoretical challenges, and there are a lot of interesting open questions.

**Rosenberger:** Many times when I hear talks on adaptive designs I want to scream out “Nancy Flournoy thought of that in the 1980s.” How do you feel about some of your early ideas being ignored?

**Flournoy:** Well, I’m hardly alone in this. For instance, Chris Jennison invented many clever techniques for sequential and adaptive clinical trials very early that are sometimes “rediscovered” without reference (e.g., Jennison, Johnstone and Turnbull, 1982; Kulkarni and Jennison, 1986; Jennison, 1987). In my case, it amazes me that there are a large number of people who will reference a paper from the 1980s and ignore 30 years of my research. For example, the early up and down paper of Storer (1989) is often cited without reference to my later papers that have much more sophisticated control of the adaptive process. This early paper is used as a whipping post to declare up and down procedures inferior. An up and down design is a random walk that can end anywhere. The last state (dose) visited should not be used as an estimator. But this is done when the up and down design is compared to other procedures that derive from stochastic approximation (e.g., Zacks, 2009). That bothers me a lot.

**Rosenberger:** How did you meet Steve Durham? This began one of the great collaborations in statistics. Tell us about that.

**Flournoy:** One of the few positive consequences of the 1989 JSM session was meeting Steve Durham from the University of South Carolina. When I walked out the door after the session, Steve introduced himself and was very excited because we were basically working

on the same mathematical problems, his from an engineering motivation, and mine from a medical motivation. We began working together right away. He would come to Washington, DC, to meet me, and I went to South Carolina. After a stint as Chair at AU, I was on a sabbatical at the University of North Carolina Chapel Hill; Leonard and I bought a house close to campus so that we could host visitors. In particular, Steve Durham and I worked together quite a lot in that house and at the Department of Statistics. Several other collaborators came down for extended periods, including you (W.F.R.) and two of my doctoral students: Eloi Kpamagen (now at Novavax) and Misrak Gezmu (now at National Institutes of Health).

**Rosenberger:** The introduction of the random walk rules coincided with the introduction of the continual reassessment method (CRM; O’Quigley, Pepe, and Fisher, 1990) in the Bayesian context. In particular, you and Steve worked out the entire exact distribution theory of a class of designs, while others were relying on simulation. How does this rank in terms of your contributions to statistics?

**Flournoy:** The random walk rules are extremely practical and mathematically elegant, so it was a lot of fun to develop the theory. They are the standard in many areas of science (e.g., American Society for Testing and Materials, 2010; Treutwein, 1995; National Institute of Environmental Health Sciences, 2001). The key property that we discovered was how to control the allocation coverage by introducing an appropriate bias (Durham and Flournoy, 1994). Steve was always thinking in terms of engineering applications; I was always thinking in the dose-response context. We did “reverse engineering,” in that we had a target allocation in mind, and we found design parameters to facilitate this. The designs are nonparametric in that allocation does not depend on estimates of model parameters. They are extraordinarily simple to illustrate and have exact distribution theory that is unavailable for other, more complicated designs.

**Rosenberger:** Some have lumped random walk rules in the context of generic dose escalation designs, such as the 3 + 3 design, that has no optimal properties. At the same time, Bayesian approaches, such as the CRM were becoming increasingly well-known. Talk about the historic interplay among these approaches.

**Flournoy:** Lloyd Fisher and John O’Quigley (from the University of Leeds) were hired at the Cancer Center to replace me when I left for the NSF. Lloyd and I laughed that it is not often one’s dissertation advisor replaces his student! John was initially responsible for implementing a random walk rule that I had



designed in a pilot study for a bone marrow clinical trial. He let them get away with a simple dose escalation procedure, but he and Lloyd got introduced to the subject at that time. They immediately thought of doing a Bayesian alternative, and it was published in 1990 in *Biometrics* (O'Quigley, Pepe and Fisher, 1990); the major random walk paper appeared in *Biometrics* in 1997 (Durham, Flournoy and Rosenberger, 1997). Most of the Bayesian literature was, by necessity, simulation based, whereas Steve and I were busy obtaining a complete workable probabilistic theory of the random walk procedures.

There are a number of philosophical differences among the approaches. Fedorov would call the CRM a “best intention” approach, because it involves predicting a target dose and treating the next patient at that dose, sequentially. Our approach is estimation-motivated. The idea is to get allocations into a region of interest that allows us to efficiently estimate the dose-response curve in that region.

There is also a short-memory and long-memory distinction: allocation probabilities for the random walk rule converge exponentially fast to their asymptotic limits. Alternatively with best intention designs (which to date are long-memory designs), nonrepresentative early allocations can cause the design to converge to the wrong dose (see, e.g., Azriel, Mandel and Rinott, 2011; Oron, Azriel and Hoff, 2011; Azriel, 2012). Such phenomena were observed early on in the context of stochastic approximation designs (e.g., Lai and Robbins, 1982; Bozin and Zarrop, 1991).

Adaptive optimal designs are promising long memory designs, but they depend on parameter estimates to get started. Random walk procedures that target optimal design points provide good start-up information with small sample sizes. Alternatively, one can regularize the information matrix, a “fix” that is often called “Bayesian designs” even though no posterior distribution is obtained. True Bayesian estimator updates coupled with dose allocations made in some stable optimal way, rather than in a “best intention” way are also promising.

**Rosenberger:** What is the future of adaptive designs? Do you think all clinical trials will eventually be adaptive?

**Flournoy:** I think there is a great future for adaptive designs. I think experimentation will always involve a series of trials; the question is how well one utilizes information from one to the next. There is a lot of value in relatively small but sequential trials (see Flournoy,

2014), because these trials involve many design features, including the grid size and range on which you are operating. The best use of one experiment may be to tell you how you could have better selected design characteristics; then you can refine the estimate of the target of interest.

Some of my work has been on inference and estimation following adaptive designs (e.g., Rosenberger, Flournoy and Durham, 1997; Ivanova and Flournoy, 2001; May and Flournoy, 2009; Lane, Yao and Flournoy, 2014). One has to be careful doing everything sequentially because some of the interim changes may cause final estimates to lack normality. For example, in best-intention designs, the estimate of a slope parameter can march off to infinity for some common models. Also, even if an adaptive dose-finding procedure has a fixed total sample size, the sample sizes at each dose are random variables. In up-and-down procedures, the proportion of subjects allocated to each dose tends to a constant and standard asymptotic normality results. But in many other adaptive designs, proportions of subjects allocated to each dose tend to a random variable. This causes the conditional information matrix to be random, even in the limit, in which case standard conditions for asymptotic normality fail. These are many interesting questions to be explored about adaptive designs.

## 5. WOMEN IN STATISTICS

**Rosenberger:** Talk about the creation of Pathways to the Future, its successes, and its legacy.

**Flournoy:** I went to the 1984 Annual IMS Meeting in Lake Tahoe. At that meeting, there were five women out of about 200 attendees. It became quite clear to me that this was an important place for academic statisticians to meet and focus on academic interests. In anticipation of the 1988 Fort Collins IMS meeting, which was separate from the Joint Statistical Meetings, I decided it would be great to see more women there. So I bounced ideas off Mary Ellen Bock (Purdue University) and Lynne Billard (University of Georgia). Lynne agreed to take the lead in organizing a workshop for women at the upcoming IMS meeting. Lynne had the brilliant idea of having Elizabeth Scott (University of California, Berkeley) give the keynote lecture. At that time, we were debating whether there was any gender inequity in academia, and we weren't sure. I had never experienced problems at UCLA or UW. However, when I went to the NSF, Yash Mittal (the first female director of the probability program) and I saw



FIG. 6. Nancy, husband Leonard, and Lynne Billard at their home in Chapel Hill, NC, 1994.

that there were almost no female grantees, and very few were even applying for grants.

The evening presentation by Scott really hit us very hard: she had tons of data and randomized studies on gender inequity. Any questions about inequities in how women were recruited, judged and valued were thrown out the window. Scott's way of handling this lecture was wonderful because she went through all this horribly depressing data, but she then turned around and finished the lecture by telling us what we could do to protect ourselves. She ended with two positive notes: that outcomes are not predetermined, and one can take one's career in one's own hands. Lynne ran the workshop for the next two decades, and she presented Scott's lecture with updated data every year. That lecture was the last lecture Scott gave before she passed away. I remember well that there was a palpable sigh of relief from Scott—that she could turn over her cause to the next generation.

**Rosenberger:** How did you become NSF program director? What was your experience with gender issues there?

**Flournoy:** Ingram Olkin has long been a great friend and mentor. He is the one who recommended me to the NSF for the program director position. I was the first female director in the statistics program the same year that Yash Mittal was the first female probability director. Some people had indicated to the division director their fear I was going to give all the grant money to biostatistics. I convinced him that I could represent the entire statistics field.

One day I remember answering the phone and a professor on the line yelled "I said I wanted to speak to the director," thinking a woman on the phone must be a secretary.

We had a good travel budget and I went to as many young women's lectures as I could. I would go up at the end of their talk and ask if they would be interested in applying for a grant. By the time I left NSF, the proportion of grant proposals from women was proportional to their presence in the field. A suggestion is such a small thing, and yet clearly important messages weren't being transmitted to female faculty.

**Rosenberger:** Was discrimination subtle or not so subtle when your career was developing?

**Flournoy:** Well, there was always sexist behavior and many things that were said and done are considered inappropriate or even sexual misconduct today. When I went on the job market for a fully academic position I found that many men were incredulous. Some would make outrageous comments directly to me as if I were invisible (or a man). Men in my own age category were often dismissive or oblivious to my presence. Some of the older generation was very helpful and supportive (I think of Shanti Gupta, Purdue University; Norman Johnson, University of North Carolina at Chapel Hill; Lucien LeCam, University of California, Berkeley; Ingram Olkin, Stanford University; and Manny Parzen, Texas A&M University). The younger generation just thought of me as another senior person, so they were fine.

**Rosenberger:** What is your feeling about the role of women in statistics today? I can say, from my per-




FIG. 7. Nancy, Ingram Olkin and Elizabeth Margosches (formerly with the Environmental Protection Agency) at the Campanile at University of California, Berkeley, 2003.

spective on 20 years of search committees, that from a hiring perspective, we are thrilled to have qualified women candidates and compete hard to get them. And certainly policies on tenure to allow maternity leave have vastly improved over the years, as have the composition of committees and senior administrators. Is there any work left to be done?

**Flournoy:** You can see improvement, but there are still troubling facts: just try to find a woman in the 2013 JSM awards brochure, for instance. Women are getting hired at proportional rates now, but awards, tenure and advancement are areas where there much is left to be done. See Lynne Billard's new update of Scott's old data on the subject (Billard and Kafadar, 2015). That will depress you.

## 6. CONCLUSION

**Rosenberger:** You talked a little about your transition into a fully academic position. The latter part of your career was spent at AU and University of Missouri (MU), and considerable time as department chair, and a mentor to many diverse students. Talk about this.

**Flournoy:** AU was a great place for me when I went there in 1988. I had left the Cancer Center with a staff of 23, a budget of \$700,000 and responsibilities that

had become a burden when I became convinced of the need for more nimble learning strategies in dose-finding clinical trials. I had eight doctoral students at AU, and all but two of them developed mechanisms to control random walks and urn models, and to provide mathematical descriptions of their controlled behavior. One worked on issues of inference following an adaptive design and one worked on a problem in economics. I am proud that four of these students are black and two are women.

Unfortunately, a very destructive president came to AU, and by 2000 it was clear that STEM graduate programs were going to be dismantled. AU had one of the oldest statistics doctoral programs in the country and it was sad to see it threatened by ignorance and arrogance. To remain in a department with a doctoral program, I needed to move and this led me to accept the chair at Missouri in 2002. When I stepped down as chair in 2011, I had doubled the number of tenure-track faculty and added five teaching faculty positions. I increased the presence of the department across campus through joint appointments and a targeted increase in service courses, and I increased the prestige of the department nationally, personally promoting our faculty and enabling their participation in national and international activities. More details can be found in a Chap-



FIG. 8. Nancy near Aasgard Pass in the Enchantment Lakes Wilderness Area, Washington, where she was hiking with her husband Leonard and her colleague Lori L. Thombs (University of Missouri) following the 2006 Joint Statistical Meetings in Seattle.

ter I recently wrote on the history of statistics at MU (Flournoy and Galen, 2012).

I have graduated seven doctoral students from MU. We worked on adaptive and optimal designs; we developed new models for specific, challenging dose-response problems and we have illuminated the effect of having dose allocations depend on the history of prior allocations and responses. My students continue to bring me a great deal of pleasure.

**Rosenberger:** What are your hobbies and interests?

**Flournoy:** I love hiking. I am not happy with a trip that takes less than four days. A four-day trip has two days out and two days back—so one is never very far from a road. After hiking for more than two days, one must rely on one's self much more completely. It is so peaceful. I gave up trying to hike in the East and the Midwest United States. One just can't get far enough away from roads; and the mountains aren't high enough. I like trekking around timberline for a week or more where the views are spectacular. I keep going back to Yosemite, Kings Canyon and Sequoia National Forests. Nepal was great, too. I try to get in one long hike each year. In the meantime, I dance. I resumed ballet classes while at AU; it is great mind-to-body exercise and wonderful for strength and balance.

Leonard and I enjoy English country dance together. Throw in Pilates and yoga and I am happy.

To survive a severe health challenge that had the doctors stumped, I gained considerable knowledge of alternative methods and became accomplished in some. But that is another story.

**Rosenberger:** What's next for Nancy Flournoy?

**Flournoy:** Well I have a lot of ideas. I'm really interested in questions of inference following adaptive designs. We have some examples in two stage designs that maximum likelihood estimators are mixtures of normals; some designs lead to estimators that are normal with random variances. I think our preliminary results are generalizable, but this remains to be shown. I'm optimistic that tractable solutions to seemingly intractable problems are at hand.

## REFERENCES

- AMERICAN SOCIETY FOR TESTING AND MATERIALS (2010). Standard test method for estimating acute oral toxicity in rats. American Society for Testing and Materials, ASTM E1163-10. ASTM International, West Conshohocken, PA.
- AZRIEL, D. (2012). A note on the robustness of the continual reassessment method. *Statist. Probab. Lett.* **82** 902–906. [MR2910036](#)
- AZRIEL, D., MANDEL, M. and RINOTT, Y. (2011). The treatment versus experimentation dilemma in dose finding studies. *J. Statist. Plann. Inference* **141** 2759–2768. [MR2787743](#)
- BARTLETT, R. H., ROLOFF, D. W., CORNELL, R. G., ANDREWS, A. F., DILLON, P. W. and ZWISCHENBERGER, J. B. (1985). Extracorporeal circulation in neonatal respiratory failure: A prospective randomized study. *Pediatrics* **76** 479–487.
- BILLARD, L. and KAFADAR, K. (2015). Women in statistics: Scientific contributions versus rewards. In *Advancing Women in Science* (W. Pearson Jr., L. M. Frehill and C. L. McNeely, eds.) Chapter 7. Springer, New York.
- BOZIN, A. and ZARROP, M. (1991). Self-tuning extremum optimizer convergence and robustness. In *Proc. 1st European Control Conf.* 91 672–677. World Scientific, Singapore.
- DURHAM, S. D. and FLOURNOY, N. (1994). Random walks for quantile estimation. In *Statistical Decision Theory and Related Topics, V (West Lafayette, IN, 1992)* 467–476. Springer, New York. [MR1286322](#)
- DURHAM, S. D., FLOURNOY, N. and ROSENBERGER, W. F. (1997). A random walk rule for phase I clinical trials. *Biometrics* **53** 745–760.
- FLOURNOY, N. (1993). A clinical experiment in bone marrow transplantation: Estimating a percentile point of a quantal response curve. In *Case Studies in Bayesian Statistics* (C. Gatsonis, J. S. Hodges, R. E. Kass and N. D. Singpurwalla, eds.) 324–335. Springer, New York.
- FLOURNOY, N. (2014). A vignette of discovery. In *Past, Present and Future of Statistical Science, in Celebration of the COPSS 50th Anniversary* (X. Lin, D. Banks, C. Genest, G. Molenaar, D. Scott and J.-L. Wang, eds.) 349–358. Chapman & Hall/CRC, Boca Raton, FL.

- FLOURNOY, N. and GALEN, M. (2012). History of the statistics department at the University of Missouri. In *History of Statistics Departments* (A. Agresti and X.-L. Meng, eds.). Springer, New York.
- FLOURNOY, N. and HEARNE, L. B. (1981). Effects of database management on the organization and administration of clinical trials. In *First Lawrence Berkeley Laboratory Workshop on Statistical Database Management* (H. K. T. Wong, ed.) 383–387. Lawrence Berkeley National Laboratory, Menlo Park, CA.
- FLOURNOY, N. and HEARNE, L. B. (1990a). Quality control for a shared multidisciplinary database. In *Data Quality Control: Theory and Pragmatics* (G. E. Liepens and V. R. R. Uppuluri, eds.) 43–56. Dekker, New York.
- FLOURNOY, N. and HEARNE, L. B. (1990b). Sharing scientific data III: Planning and the research proposal. *IRB: A Review of Human Subject Research* **12** 6–9.
- FLOURNOY, N. and ORON, A. P. (2015). Up-and-down designs for dose-finding. In *Handbook of Design and Analysis of Experiments* (D. Bingham, A. M. Dean, M. Morris and J. Stufken, eds.) 862–898. Chapman & Hall/CRC, Boca Raton, FL.
- FLOURNOY, N. and ROSENBERGER, W. F., eds. (1995). *Adaptive Designs. Institute of Mathematical Statistics Lecture Notes—Monograph Series* **25**. IMS, Hayward, CA. [MR1477667](#)
- IVANOVA, A. and FLOURNOY, N. (2001). A birth and death urn for ternary outcomes: Stochastic processes applied to urn models. In *Advances in Statistical Theory—A Volume in Honor of Theophilos Cacoulous* (C. Charalambides, M. V. Koutras and N. Balakrishnan, eds.) 583–600. CRC Press/Chapman & Hall, Boca Raton, FL.
- JENNISON, C. (1987). Efficient group sequential tests with unpredictable group sizes. *Biometrika* **74** 155–165. [MR0885928](#)
- JENNISON, C., JOHNSTONE, I. M. and TURNBULL, B. W. (1982). Asymptotically optimal procedures for sequential adaptive selection of the best of several normal means. In *Statistical Decision Theory and Related Topics, III, Vol. 2* (West Lafayette, Ind., 1981) 55–86. Academic Press, New York. [MR0705308](#)
- KULKARNI, R. V. and JENNISON, C. (1986). Optimal properties of the Bechhofer-Kulkarni Bernoulli selection procedure. *Ann. Statist.* **14** 298–314. [MR0829570](#)
- LAI, T. L. and ROBBINS, H. (1982). Iterated least squares in multiperiod control. *Adv. in Appl. Math.* **3** 50–73. [MR0646499](#)
- LANE, A., YAO, P. and FLOURNOY, N. (2014). Information in a two-stage adaptive optimal design. *J. Statist. Plann. Inference* **144** 173–187.
- LI, Z., DURHAM, S. D. and FLOURNOY, N. (1995). An adaptive design for maximization of a contingent binary response. In *Adaptive Designs* (South Hadley, MA, 1992). *Institute of Mathematical Statistics Lecture Notes—Monograph Series* **25** 179–196. IMS, Hayward, CA. [MR1477680](#)
- LIN, Y. and SHIH, W. J. (2001). Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials. *Biostatistics* **2** 203–215.
- MAY, C. and FLOURNOY, N. (2009). Asymptotics in response-adaptive designs generated by a two-color, randomly reinforced urn. *Ann. Statist.* **37** 1058–1078. [MR2502661](#)
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES (2001). The revised up-and-down procedure: A test method for determining the acute oral toxicity of chemicals. Technical Report 2-4501, NIEHS, Washington, DC.
- O'QUIGLEY, J., PEPE, M. and FISHER, L. (1990). Continual re-assessment method: A practical design for phase I clinical trials in cancer. *Biometrics* **46** 33–48. [MR1059105](#)
- O'ROURKE, P. P., CRONE, R. K., VACANTI, J. P., WARE, J. H., LILLEHEI, C. W., PARAD, R. B. and EPSTEIN, M. F. (1989). Extracorporeal membrane oxygenation and conventional medical therapy in neonates with persistent pulmonary hypertension of the newborn: A prospective randomized study. *Pediatrics* **84** 957–963.
- ORON, A. P., AZRIEL, D. and HOFF, P. D. (2011). Dose-finding designs: The role of convergence properties. *Int. J. Biostat.* **7** Art. 39, 19. [MR2873999](#)
- ORON, A. P. and HOFF, P. D. (2013). Small sample behavior of novel phase I cancer trial designs. *Clinical Trials* **10** 63–92 (with discussion).
- PETO, R., PIKE, M. C., ARMITAGE, P., BRESLOW, N. E., COX, D. R., HOWARD, S. V., MANTEL, N., MCPHERSON, K., PETO, J. and SMITH, P. G. (1976). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. *Br. J. Cancer* **34** 585–612.
- PETO, R., PIKE, M. C., ARMITAGE, P., BRESLOW, N. E., COX, D. R., HOWARD, S. V., MANTEL, N., MCPHERSON, K., PETO, J. and SMITH, P. G. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. *Br. J. Cancer* **35** 1–39.
- REINER, E., PAOLETTI, X. and O'QUIGLEY, J. (1999). Operating characteristics of the standard phase I clinical trial design. *Comput. Statist. Data Anal.* **30** 303–315.
- ROSENBERGER, W. F., FLOURNOY, N. and DURHAM, S. D. (1997). Asymptotic normality of maximum likelihood estimators from multiparameter response-driven designs. *J. Statist. Plann. Inference* **60** 69–76. [MR1453033](#)
- STORER, B. E. (1989). Design and analysis of phase I clinical trials. *Biometrics* **45** 925–937. [MR1029610](#)
- THALL, P. F. and COOK, J. D. (2004). Dose-finding based on efficacy-toxicity trade-offs. *Biometrics* **60** 684–693. [MR2089444](#)
- TREUTWEIN, B. (1995). Minireview: Adaptive psychophysical procedures. *Vision Res.* **35** 2503–2522.
- WARE, J. H. (1989). Investigating therapies of potentially great benefit: ECMO. *Statist. Sci.* **4** 298–340. [MR1041761](#)
- WEI, L. J. and DURHAM, S. (1978). The randomized play-the-winner rule in medical trials. *J. Amer. Statist. Assoc.* **73** 840–843.
- WEIDEN, P. L., FLOURNOY, N., THOMAS, E. D., PRENTICE, R., FEFER, A., BUCKNER, C. D. and STORB, R. (1979). Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. *New Engl. J. Med.* **300** 1068–1073.
- WEIDEN, P. L., FLOURNOY, N., SANDERS, J. E., SULLIVAN, K. M. and THOMAS, E. D. (1981a). Antileukemic effect of graft-versus-host disease contributes to improved survival after allogeneic marrow transplantation. *Transplant. Proc.* **13** 248–251.
- WEIDEN, P. L., SULLIVAN, K. M., FLOURNOY, N., STORB, R., THOMAS, E. D. and THE SEATTLE BONE MARROW TRANSPLANT TEAM (1981b). Antileukemic effect of chronic graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. *New Engl. J. Med.* **304** 1529–1533.

WEIDEN, P. L., FLOURNOY, N., THOMAS, E. D., FEFER, A. and STORB, R. (1981c). Antitumor effect of marrow transplantation in human recipients of syngeneic or allogeneic grafts. In *Graft-Versus-Leukemia in Man and Animal Models* (J. Okunewick and

R. Meredith, eds.) 11–23. CRC Press, Boca Raton, FL.  
ZACKS, S. (2009). *Stage-wise Adaptive Designs*. Wiley, Hoboken, NJ. MR2559830